Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma
NCT00720447Phase 2Unknown
- Sponsor
- Cancer Research UK
- Start
- Nov 2008
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in mantle cell lymphoma (MCL), sponsored by Cancer Research UK. Primary endpoint: Progression-Free Survival. Status: unknown.
02
Drugs
alemtuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00720447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00720447.